Johnson & Johnson Reports Q3 Sales Growth, Maintains Full-Year Guidance
US giant Johnson & Johnson (J&J, NYSE: JNJ) released its Q3 2022 financial report, showing...
Sichuan Biokin Pharma Plans IPO on STAR Board to Raise RMB 1.422 Billion
China-based Sichuan Biokin Pharmaceutical Co., Ltd is set to conduct an initial public offering (IPO)...
Mabwell Bioscience’s 9MW3011 Accepted for Review by China’s NMPA
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that its clinical filing for...
Zhiyi Biotechnology Receives FDA Clearance for SK10 in Chemotherapy-Induced Diarrhea
Guangzhou-based Zhiyi Biotechnology has announced receiving clearance from the US FDA for a clinical study...
Shanghai’s Hrain Biotechnology Plans IPO on STAR Board to Raise RMB 2.539 Billion
Shanghai-based Hrain Biotechnology Co., Ltd, a specialist in tumor immunotherapy, plans to conduct an initial...
Eucure Biopharma Partners with Syncromune on Intratumoral Immunotherapy
Eucure Biopharma, a wholly-owned subsidiary of Sino-US contract research organization (CRO) Biocytogen, has entered into...
Abogen Biosciences Receives UAE Clinical Trial Approval for Omicron BA.4/5 mRNA Vaccine
China’s Abogen Biosciences Co., Ltd, a developer of messenger ribonucleic acid (mRNA) drugs, has announced...
Shenzhen GeneBioHealth Secures USD 15M for Bio-Business Expansion
Shenzhen GeneBioHealth Co., Ltd, a China-based in-vitro diagnostic (IVD) medical device developer, has reportedly raised...
CSPC’s Generic Xofluza Gains NMPA Approval Amid Roche Patent Dispute
China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) has obtained market approval from the National...
Gracell Biotechnologies Initiates Phase II Dosing for GC007g in B-ALL Patients
China-based Gracell Biotechnologies Inc. has announced the first patient dosing in the Phase II portion...
Henlius Biotech Gains NMPA Approval for Phase I Trial of HLX60 in Solid Tumors and Lymphomas
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced receiving approval from the National Medical Products...
PureID Medical Technology Secures RMB 100M Series B Funding
PureID Medical Technology Co., Ltd, a medical device compliance service provider based in Guangzhou, has...
Sinocelltech’s COVID-19 Vaccines SCTV01C and SCTV01E Show Promising Phase III Results
China-based Sinocelltech Group Ltd (SHA: 688520) has announced the preliminary interim analysis results of a...
Jemincare’s Sonidegib Receives First Prescriptions in China for Basal Cell Carcinoma
China-based Jiangxi Jemincare Group has announced the first prescriptions in China for its sonidegib, a...
Salus Biomed Raises Over RMB 100M in Pre-Series A Financing
Salus Biomed, a sequencing and spatial omics platform provider based in Guangdong, has reportedly raised...
Haisco Pharma’s Ciprofol Injection Gains NMPA Approval for Gynecology Use
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced receiving another marketing approval from...
ScienCare Pharma’s Naltrexone Implant Prioritized for Review by CDE
The Center for Drug Evaluation (CDE) website indicates that the market filing by China-based Shenzhen...
Grand Pharma’s TLX591-CDx Approved for Prostate Cancer Diagnosis in China
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its Investigational New Drug (IND)...
Kunshi Biotechnology Raises Angel Funding for Engineered Macrophage Platform
China-based Kunshi Biotechnology (Shenzhen) Co., Ltd, a company specializing in gene editing, biomaterials, and synthetic...
Akeso Biopharma’s Cadonilimab Recommended as First-Line Treatment for Cervical Cancer
China-based biotech Akeso Biopharma (HKG: 9926) has revealed that its cadonilimab (AK104) has been included...